

P&T Motion History Atopic Dermatitis

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
dupilumab crisaborole pimecrolimus tacrolimus	After considering the evidence of safety, efficacy and special populations for the treatment of Atopic Dermatitis, I move that dupilumab, crisaborole, pimecrolimus, and tacrolimus are safe and efficacious for the treatment of their approved indications. The calcineuran inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Figueroa 2nd: Chew	October 16, 2019	Yes Brown Fletebo	Yes Huynh Schwilke	Passed unanimous